R. Siegel, D. Naishadham, and A. Jemal, CA: a cancer journal for clinicians, vol.62, pp.10-29, 2012.

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu et al., CA: a cancer journal for clinicians, vol.58, pp.71-96, 2008.

R. E. Bristow, R. S. Tomacruz, D. K. Armstrong, E. L. Trimble, and F. J. Montz, Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis, J Clin Oncol, vol.20, issue.5, pp.1248-59, 2002.

W. P. Mcguire, W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge et al., Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England journal of medicine, vol.334, pp.1-6, 1996.

I. Vergote, C. G. Trope, F. Amant, G. B. Kristensen, T. Ehlen et al., Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer, N Engl J Med, vol.363, issue.10, pp.943-53, 2010.

T. W. Burke and M. Morris, Secondary cytoreductive surgery for ovarian cancer, Obstetrics and gynecology clinics of North America, vol.21, issue.1, pp.167-78, 1994.

M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins et al., Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, vol.9, issue.3, pp.389-93, 1991.

R. W. Naumann and R. L. Coleman, Management strategies for recurrent platinum-resistant ovarian cancer, Drugs, vol.71, issue.11, pp.1397-412, 2011.

D. S. Alberts, P. Y. Liu, S. P. Wilczynski, M. C. Clouser, A. M. Lopez et al., Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecologic oncology, vol.108, p.2276605, 2008.

E. Pujade-lauraine, U. Wagner, E. Aavall-lundqvist, V. Gebski, M. Heywood et al., Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse, Epub 2010/05/26, vol.28, pp.3323-3332, 2010.

M. Luyckx, E. Leblanc, T. Filleron, P. Morice, E. Darai et al., Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study, Int J Gynecol Cancer, vol.22, issue.8, pp.1337-1380, 2012.

J. Esquivel, A. Farinetti, and P. H. Sugarbaker, Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed

. Chir, , vol.20, pp.81-87, 1999.

A. Bois, H. J. Luck, W. Meier, H. P. Adams, V. Mobus et al., A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, Journal of the National Cancer Institute, vol.95, issue.17, pp.1320-1329, 2003.

J. Pfisterer, B. Weber, A. Reuss, R. Kimmig, A. Du-bois et al., Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO, Journal of the National Cancer Institute, vol.98, issue.15, pp.1036-1081, 2006.

A. Bois, B. Weber, J. Rochon, W. Meier, A. Goupil et al., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens, Journal of clinical oncology: official journal of the American Society of Clinical Oncology, vol.24, issue.7, pp.1127-1162, 2006.

A. Du-bois, . Ra, E. Pujade-lauraine, P. Harter, I. Ray-coquard et al., Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO), Cancer, vol.115, issue.6, pp.1234-1278, 2009.

. Harter-p-dba, M. Hahmann, A. Hasenburg, A. Burges, S. Loibl et al.,

, Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial, Annals of surgical oncology, vol.13, issue.12, pp.1702-1712, 2006.

J. Alexandre, I. Ray-coquard, S. F. Floquet, A. Cottu, P. Weber et al., Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience, Medical Oncology / ESMO, vol.21, issue.12, pp.2377-81, 2010.

E. Tagliabue, R. Agresti, M. L. Carcangiu, C. Ghirelli, D. Morelli et al., Role of HER2 in woundinduced breast carcinoma proliferation, Lancet, vol.362, issue.9383, pp.14112-14120, 2003.

C. F. Singer, G. Hudelist, E. M. Fuchs, W. Kostler, A. Fink-retter et al., Incomplete surgical resection of ductal carcinomas in situ results in activation of ERBB2 in residual breast cancer cells. Endocrine-related cancer, vol.16, pp.73-83, 2009.

P. Impellizzeri, A. Simona, M. Grasso, P. Antonuccio, C. Crisafi et al., Surgical Stress after Open and Transumbilical Laparoscopic-Assisted Appendectomy in Children. European journal of pediatric surgery: official journal of Austrian Association of Pediatric Surgery [et al] = Zeitschrift fur Kinderchirurgie, 2013.

Y. Wang, X. L. Niu, Y. Qu, J. Wu, Y. Q. Zhu et al., Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer letters, Epub 2010/03/20, vol.295, pp.110-133, 2010.

Y. Wang, Y. Qu, X. L. Niu, W. J. Sun, X. L. Zhang et al., Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells, Cytokine, vol.56, issue.2, pp.365-75, 2011.

C. Touboul, R. Lis, A. Farsi, H. Raynaud, C. M. Warfa et al., Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D model, J Transl Med, vol.11, p.28, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-00794947

P. Central and P. , , p.3582577

R. Lis, C. Touboul, C. M. Raynaud, J. A. Malek, K. Suhre et al., Mesenchymal cell interaction with ovarian cancer cells triggers pro-metastatic properties, PLoS One, vol.7, issue.5, p.3364218, 2012.